Rhode Island is currently home to 505 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Providence, Warwick, East Providence and Johnston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
NCT05464030
Recruiting
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary clinical activity of M9140 in advanced solid tumors. This study contains 2 parts: Dose escalation (Part 1) and dose expansion (Part 2). Study details include: * Study Duration per participant: Approximately 4 months for Part 1 and 8 months for Part 2 * M9140 is not available through an expanded access program
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Rhode Island Hospital, Providence, Rhode Island
Conditions: Colorectal Cancer
Register for Updates
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
NCT05312879
Recruiting
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Gender:
ALL
Ages:
Between 10 years and 65 years
Trial Updated:
07/24/2025
Locations: Lifespan Clinical Research Center, East Providence, Rhode Island
Conditions: Proteinuric Kidney Disease
Register for Updates
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
NCT04486378
Recruiting
This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Rhode Island Hospital, Providence, Rhode Island
Conditions: Colorectal Cancer Stage II, Colorectal Cancer Stage III
Register for Updates
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395
Recruiting
This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary goal of the study is to assess the efficacy and safety of multiple interventions following intravenous (IV) induction and subcutaneous (SC) maintenance treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Site 025, Providence, Rhode Island
Conditions: Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
Register for Updates
A 2-stage, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
NCT06015737
Recruiting
This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with cutaneous lupus erythematosus (CLE).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/23/2025
Locations: Research Site, Providence, Rhode Island
Conditions: Cutaneous Lupus Erythematosus
Register for Updates
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168
Recruiting
This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/23/2025
Locations: Research Site, Providence, Rhode Island
Conditions: Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer
Register for Updates
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
NCT05503797
Recruiting
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with rare BRAF V600-mutated solid tumors, melanoma, thyroid, or recurrent primary CNS tumors.
Gender:
ALL
Ages:
10 years and above
Trial Updated:
07/23/2025
Locations: Lifespan Cancer Institute - Rhode Island Hospital, Providence, Rhode Island
Conditions: Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors, Melanoma BRAF V600E/K Mutated, Thyroid Cancer
Register for Updates
An Adaptive Intervention to Increase Engagement to Community-Based Care After an ED Admission
NCT07092345
Recruiting
The goal of this study is to develop a feasible brief, family-based adaptive intervention, via SMART design, for youth with suicidal and non-suicidal self-injurious behavior (SSIB) to increase community-based mental health (MH) care attendance and reduce SSIB risk post emergency department (ED) admission. The intervention will focus to increase understanding on youth MH literacy, MH communication, and MH engagement. Integrating an adaptive intervention via a SMART design in the ED could address... Read More
Gender:
ALL
Ages:
Between 8 years and 17 years
Trial Updated:
07/22/2025
Locations: Hasbro Children's Hospital, Providence, Rhode Island
Conditions: Suicidal and Self-injurious Behavior, Linkage to Care
Register for Updates
A Sleep Hygiene Intervention to Improve Sleep Health in Urban, Latino Middle School Children
NCT06942455
Recruiting
The main goal of this study is to evaluate the "SIESTA" intervention, a culturally and contextually tailored sleep hygiene intervention that has the potential to exert greater improvements in sleep hygiene and sleep outcomes for group that may be more vulnerable to poor sleep health. The main question is: do SIESTA participants have improved sleep outcomes, sleep hygiene behaviors and less sleep-related impairment compared to Control Group participants? Participants randomized to the SIESTA in... Read More
Gender:
ALL
Ages:
Between 11 years and 13 years
Trial Updated:
07/22/2025
Locations: Rhode Island Hospital, Providence, Rhode Island
Conditions: Sleep, Sleep Quality, Intervention Study, Ethnic Minority
Register for Updates
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 61 weeks.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/22/2025
Locations: University Gastroenterology - Providence - West River Street, Providence, Rhode Island
Conditions: Crohn's Disease, Obesity or Overweight
Register for Updates
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086
Recruiting
The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation in this study will last up to 61 weeks, including 52 weeks of treatment.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/22/2025
Locations: University Gastroenterology - Providence - West River Street, Providence, Rhode Island
Conditions: Ulcerative Colitis, Obesity or Overweight
Register for Updates
Evaluation of Delefilcon A Contact Lenses
NCT06884202
Recruiting
The purpose of the study is to evaluate the lens fit characteristics of delefilcon A contact lenses with different base curves and diameters.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: West Bay Eye Associates, Warwick, Rhode Island
Conditions: Refractive Errors, Myopia
Register for Updates